Jiang Ma
Jiang Ma has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Ge Lin
School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China
8 shared publications - Yisheng He
School of Medicine The Chinese University of Hong Kong Shenzhen Guangdong China
6 shared publications Yang Ye
State Key Laboratory of Drug Research and Natural Products Chemistry Department, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
3 shared publications- Jia Liu
Shanghai Institute of Materia Medica, Chinese Academy of Sciences
2 shared publications - Peter P. Fu
National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, Arkansas 72079, United States
2 shared publications Sheng Yao
State Key Laboratory of Drug Research and Natural Products Chemistry Department, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
2 shared publications
Latest Publications
- Open Access
- 31 August 2026
- Published by Elsevier in Chinese Herbal Medicines
- Vol. 18 (4) , 939-959
Gut-liver axis and intestinal microbiota: Key targets of herbal medicines in treatment of MASLD/MASH
- 31 August 2026
- Published by Elsevier in Chinese Herbal Medicines
- Vol. 18 (4) , 939-959
Open AccessGut-liver axis and intestinal microbiota: Key targets of herbal medicines in treatment of MASLD/MASH
- 24 November 2025
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 73 (49) , 31543-31558
Deciphering the Distinct Vascular Liver Injury Induced by Pyrrolizidine Alkaloids: From the Invasive Species to Health Hazard
Pyrrolizidine alkaloids (PAs) are the most common plant-derived toxins present in numerous herbal and food products, but their environmental transfer pathways and toxicological mechanisms remain unclear. This study establishes a complete contamination pathway from environmental source to molecular target. We identified the invasive plant Bidens alba as a novel PA producer and provided the first evidence of transfer to honey by detecting corresponding PAs and characteristic Bidens alba pollens in local samples. Mechanistically, we demonstrated that PA toxicity fundamentally differs from classic hepatotoxins like acetaminophen. Instead of directly damaging liver cells, PAs first induce red blood cell rupture (hemolysis) by selectively inhibiting glucose-6-phosphate dehydrogenase (G6PD). This hemolytic event precedes observable liver sinusoidal endothelial damage and initiates characteristic vascular liver injury. Our findings establish a new route of food contamination and redefine PA toxicity by identifying blood cells as the primary target, with significant implications for food safety and public health.
- 24 November 2025
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 73 (49) , 31543-31558
Deciphering the Distinct Vascular Liver Injury Induced by Pyrrolizidine Alkaloids: From the Invasive Species to Health Hazard
Pyrrolizidine alkaloids (PAs) are the most common plant-derived toxins present in numerous herbal and food products, but their environmental transfer pathways and toxicological mechanisms remain unclear. This study establishes a complete contamination pathway from environmental source to molecular target. We identified the invasive plant Bidens alba as a novel PA producer and provided the first evidence of transfer to honey by detecting corresponding PAs and characteristic Bidens alba pollens in local samples. Mechanistically, we demonstrated that PA toxicity fundamentally differs from classic hepatotoxins like acetaminophen. Instead of directly damaging liver cells, PAs first induce red blood cell rupture (hemolysis) by selectively inhibiting glucose-6-phosphate dehydrogenase (G6PD). This hemolytic event precedes observable liver sinusoidal endothelial damage and initiates characteristic vascular liver injury. Our findings establish a new route of food contamination and redefine PA toxicity by identifying blood cells as the primary target, with significant implications for food safety and public health.
- Open Access
- 18 May 2023
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 385 (S3) , 58
Investigation of hepatotoxicity of structurally diverse pyrrolizidine alkaloids in zebrafish model
ID 53680 Poster Board 58 Pyrrolizidine alkaloids (PAs) are hepatotoxic phytotoxins distributed in over 6000 plant species worldwide and pose a potential threat to human health via exposure to PA-contaminated foods and herbal medicines/supplements. PA-induced hepatotoxicity is due to metabolic activation in the liver to generate toxic metabolites, and significantly different hepatotoxic potencies have been demonstrated with structurally diverse PAs. Therefore, understanding of hepatotoxic potencies of different PAs is the prerequisite for establishing an appropriate risk assessment of PA exposure. In the present study, we used zebrafish model for evaluating hepatotoxic potency of 9 different PAs, because the zebrafish model can mimic the physiological processes, in particular the hepatic metabolism, in the body. At 6 hours after oral administration, individual PAs exhibited distinct structure-dependent hepatotoxic potencies in zebrafish, evidenced by a series of biochemical and histological detrimental changes in the liver. The assessed hepatotoxic potency order was determined to be lasiocarpine ∼ retrorsine > monocrotaline > riddelliine > clivorine > heliotrine > retrorsine N-oxide ∼ riddelliine N-oxide >>> platyphylline. In addition, compared to the control group, varied up- or down-regulated mRNA expressions in different PA treatment groups indicated that inflammation, apoptosis, and steatosis in the liver were all involved in PA-induced hepatotoxicity. Our findings demonstrated that zebrafish is a capable model for screening the hepatotoxicity and ranking the toxic potencies of different PAs, and the results obtained would assist the establishment of a more appropriate regulation for risk assessment of PA exposure. This study was supported by Research Grant Council of Hong Kong SAR (GRF Grant No. 14106120) and CUHK Direct Grant (Grant No. 4054656)
- 18 May 2023
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 385 (S3) , 58
Open AccessInvestigation of hepatotoxicity of structurally diverse pyrrolizidine alkaloids in zebrafish model
ID 53680 Poster Board 58 Pyrrolizidine alkaloids (PAs) are hepatotoxic phytotoxins distributed in over 6000 plant species worldwide and pose a potential threat to human health via exposure to PA-contaminated foods and herbal medicines/supplements. PA-induced hepatotoxicity is due to metabolic activation in the liver to generate toxic metabolites, and significantly different hepatotoxic potencies have been demonstrated with structurally diverse PAs. Therefore, understanding of hepatotoxic potencies of different PAs is the prerequisite for establishing an appropriate risk assessment of PA exposure. In the present study, we used zebrafish model for evaluating hepatotoxic potency of 9 different PAs, because the zebrafish model can mimic the physiological processes, in particular the hepatic metabolism, in the body. At 6 hours after oral administration, individual PAs exhibited distinct structure-dependent hepatotoxic potencies in zebrafish, evidenced by a series of biochemical and histological detrimental changes in the liver. The assessed hepatotoxic potency order was determined to be lasiocarpine ∼ retrorsine > monocrotaline > riddelliine > clivorine > heliotrine > retrorsine N-oxide ∼ riddelliine N-oxide >>> platyphylline. In addition, compared to the control group, varied up- or down-regulated mRNA expressions in different PA treatment groups indicated that inflammation, apoptosis, and steatosis in the liver were all involved in PA-induced hepatotoxicity. Our findings demonstrated that zebrafish is a capable model for screening the hepatotoxicity and ranking the toxic potencies of different PAs, and the results obtained would assist the establishment of a more appropriate regulation for risk assessment of PA exposure. This study was supported by Research Grant Council of Hong Kong SAR (GRF Grant No. 14106120) and CUHK Direct Grant (Grant No. 4054656)
- 13 May 2022
- Published by Elsevier in Phytomedicine
- Vol. 102, 154162
Nrf2-mediated liver protection by 18β-glycyrrhetinic acid against pyrrolizidine alkaloid-induced toxicity through PI3K/Akt/GSK3β pathway
- 13 May 2022
- Published by Elsevier in Phytomedicine
- Vol. 102, 154162
Nrf2-mediated liver protection by 18β-glycyrrhetinic acid against pyrrolizidine alkaloid-induced toxicity through PI3K/Akt/GSK3β pathway
- 1 August 2021
- Published by Elsevier in Phytomedicine
- Vol. 89, 153595
Characterization of liver injury induced by a pyrrolizidine alkaloid in rats
- 1 August 2021
- Published by Elsevier in Phytomedicine
- Vol. 89, 153595
Characterization of liver injury induced by a pyrrolizidine alkaloid in rats
- 15 June 2021
- Published by American Chemical Society (ACS) in Environmental Science & Technology Letters
- Vol. 8 (7) , 551-557
Blood Pyrrole–DNA Adducts Define the Early Tumorigenic Risk in Patients with Pyrrolizidine Alkaloid-Induced Liver Injury
- 15 June 2021
- Published by American Chemical Society (ACS) in Environmental Science & Technology Letters
- Vol. 8 (7) , 551-557
Blood Pyrrole–DNA Adducts Define the Early Tumorigenic Risk in Patients with Pyrrolizidine Alkaloid-Induced Liver Injury
- 18 November 2020
- Published by Springer Nature in Archives of Toxicology
- Vol. 95 (2) , 759-765
Clinical application of pyrrole–hemoglobin adducts as a biomarker of pyrrolizidine alkaloid exposure in humans
Pyrrolizidine alkaloids (PAs) are naturally occurring hepatotoxins widely present in hundreds of plant species and also known to contaminate many foodstuffs, such as grain, honey, and tea. The formation of pyrrole–protein adducts via metabolic activation of PAs has been suggested as a primary trigger initiating hepatotoxicity. The present study for the first time tested the suitability of pyrrole–hemoglobin adducts as a novel and specific biomarker of PA exposure in humans. The level and elimination kinetics of pyrrole–hemoglobin adducts were systematically investigated in the blood samples of 43 PA-induced liver injury (PA-ILI) patients. The results revealed significantly higher concentrations (84.50 ± 78.38 nM) and longer persistence (~ 4 months) of pyrrole–hemoglobin adducts than that (concentration: 9.53 ± 10.72 nM; persistence: ~ 2 months) of pyrrole–plasma protein adducts, our previously developed PA exposure biomarker. Our findings confirmed that pyrrole–hemoglobin adducts with higher level and longer persistence should serve as a more applicable PA exposure biomarker for future clinical diagnosis of PA-ILI in drug/herb-induced liver injury patients.
- 18 November 2020
- Published by Springer Nature in Archives of Toxicology
- Vol. 95 (2) , 759-765
Clinical application of pyrrole–hemoglobin adducts as a biomarker of pyrrolizidine alkaloid exposure in humans
Pyrrolizidine alkaloids (PAs) are naturally occurring hepatotoxins widely present in hundreds of plant species and also known to contaminate many foodstuffs, such as grain, honey, and tea. The formation of pyrrole–protein adducts via metabolic activation of PAs has been suggested as a primary trigger initiating hepatotoxicity. The present study for the first time tested the suitability of pyrrole–hemoglobin adducts as a novel and specific biomarker of PA exposure in humans. The level and elimination kinetics of pyrrole–hemoglobin adducts were systematically investigated in the blood samples of 43 PA-induced liver injury (PA-ILI) patients. The results revealed significantly higher concentrations (84.50 ± 78.38 nM) and longer persistence (~ 4 months) of pyrrole–hemoglobin adducts than that (concentration: 9.53 ± 10.72 nM; persistence: ~ 2 months) of pyrrole–plasma protein adducts, our previously developed PA exposure biomarker. Our findings confirmed that pyrrole–hemoglobin adducts with higher level and longer persistence should serve as a more applicable PA exposure biomarker for future clinical diagnosis of PA-ILI in drug/herb-induced liver injury patients.
- 2 April 2020
- Published by Taylor & Francis in Journal of Environmental Science and Health, Part C
- Vol. 38 (2) , 169-185
Establishment of a novel CYP3A4-transduced human hepatic sinusoidal endothelial cell model and its application in screening hepatotoxicity of pyrrolizidine alkaloids
Pyrrolizidine alkaloids (PAs) are extensively distributed in plants and are known to damage hepatic sinusoidal endothelial cells (HSECs) via metabolic activation mediated by hepatic cytochrome P450 enzymes (CYPs), particularly the CYP3A4 isozyme. Different PAs have distinct toxic potencies and their toxic effects on HSECs are difficult to be determined in cultured cells, because HSECs lack the key CYP3A4 isozyme for metabolic activation. This study aims to establish a novel, convenient and reliable CYP3A4-expressing HSEC model using human HSECs transduced with lentivirus carrying CYP3A4-ires-eGFP, for evaluating the hepatotoxicity of different PAs on their target HSECs. The developed CYP3A4-expressing HSEC (HSEC-CYP3A4) model was verified by the expression of GFP and CYP3A4 and by the ability to metabolize nifedipine, a classic CYP3A4 substrate. Treated with retrorsine, a representative toxic PA, HSEC-CYP3A4 cells showed significantly reduced cell viability, depletion of GSH, and increased formation of pyrrole-protein adducts. Furthermore, this newly developed cell model successfully discriminated the cytotoxic potency of different PAs evidenced by their IC40 values. In conclusion, the established HSEC-CYP3A4 cell model can be used as a rapid screening platform for assessing the relative potencies of individual PAs on their target HSECs and for investigating the mechanisms underlying PA-induced hepatic sinusoidal damage.
- 2 April 2020
- Published by Taylor & Francis in Journal of Environmental Science and Health, Part C
- Vol. 38 (2) , 169-185
Establishment of a novel CYP3A4-transduced human hepatic sinusoidal endothelial cell model and its application in screening hepatotoxicity of pyrrolizidine alkaloids
Pyrrolizidine alkaloids (PAs) are extensively distributed in plants and are known to damage hepatic sinusoidal endothelial cells (HSECs) via metabolic activation mediated by hepatic cytochrome P450 enzymes (CYPs), particularly the CYP3A4 isozyme. Different PAs have distinct toxic potencies and their toxic effects on HSECs are difficult to be determined in cultured cells, because HSECs lack the key CYP3A4 isozyme for metabolic activation. This study aims to establish a novel, convenient and reliable CYP3A4-expressing HSEC model using human HSECs transduced with lentivirus carrying CYP3A4-ires-eGFP, for evaluating the hepatotoxicity of different PAs on their target HSECs. The developed CYP3A4-expressing HSEC (HSEC-CYP3A4) model was verified by the expression of GFP and CYP3A4 and by the ability to metabolize nifedipine, a classic CYP3A4 substrate. Treated with retrorsine, a representative toxic PA, HSEC-CYP3A4 cells showed significantly reduced cell viability, depletion of GSH, and increased formation of pyrrole-protein adducts. Furthermore, this newly developed cell model successfully discriminated the cytotoxic potency of different PAs evidenced by their IC40 values. In conclusion, the established HSEC-CYP3A4 cell model can be used as a rapid screening platform for assessing the relative potencies of individual PAs on their target HSECs and for investigating the mechanisms underlying PA-induced hepatic sinusoidal damage.
- 2 April 2020
- Published by Taylor & Francis in Journal of Environmental Science and Health, Part C
- Vol. 38 (2) , 124-140
Pulmonary toxicity is a common phenomenon of toxic pyrrolizidine alkaloids
The hepatotoxic pyrrolizidine alkaloids (PAs) are metabolically activated in the liver to form reactive dehydro-PAs, which generate pyrrole-protein adducts leading to hepatotoxicity. Monocrotaline, but not other PAs, is also pneumotoxic, supposedly due to the migration of the liver-generated corresponding dehydro-PA into the lung to form pyrrole-protein adducts to induce pneumotoxicity. The present study investigated whether other PAs are also pneumotoxic. Metabolic activation of four representative hepatotoxic PAs, monocrotaline, retrorsine, riddelliine and clivorine, was investigated using rat liver or lung S9 incubation. All PAs produced pyrrole-protein adducts significantly in rat liver S9 but negligible in lung S9 fraction, revealing that liver is the key organ responsible for metabolic activation generating dehydro-PAs. Furthermore, these four PAs and another two PAs present in the alkaloid extract of Gynura segetum, a widely used PA-producing herb responsible for human PA poisonings in China, were orally administered to rats using the same hepatotoxic dose of 0.2 mmol/kg. All six PAs induced pneumotoxicity in rats within 48 h. The results demonstrated that pneumotoxicity could be a common phenomenon of PAs and the liver-derived dehydro-PAs might move to the lung and form pyrrole-protein adducts, leading to pulmonary toxicity.
- 2 April 2020
- Published by Taylor & Francis in Journal of Environmental Science and Health, Part C
- Vol. 38 (2) , 124-140
Pulmonary toxicity is a common phenomenon of toxic pyrrolizidine alkaloids
The hepatotoxic pyrrolizidine alkaloids (PAs) are metabolically activated in the liver to form reactive dehydro-PAs, which generate pyrrole-protein adducts leading to hepatotoxicity. Monocrotaline, but not other PAs, is also pneumotoxic, supposedly due to the migration of the liver-generated corresponding dehydro-PA into the lung to form pyrrole-protein adducts to induce pneumotoxicity. The present study investigated whether other PAs are also pneumotoxic. Metabolic activation of four representative hepatotoxic PAs, monocrotaline, retrorsine, riddelliine and clivorine, was investigated using rat liver or lung S9 incubation. All PAs produced pyrrole-protein adducts significantly in rat liver S9 but negligible in lung S9 fraction, revealing that liver is the key organ responsible for metabolic activation generating dehydro-PAs. Furthermore, these four PAs and another two PAs present in the alkaloid extract of Gynura segetum, a widely used PA-producing herb responsible for human PA poisonings in China, were orally administered to rats using the same hepatotoxic dose of 0.2 mmol/kg. All six PAs induced pneumotoxicity in rats within 48 h. The results demonstrated that pneumotoxicity could be a common phenomenon of PAs and the liver-derived dehydro-PAs might move to the lung and form pyrrole-protein adducts, leading to pulmonary toxicity.
- 23 April 2019
- Published by American Chemical Society (ACS) in Chemical Research in Toxicology
- Vol. 32 (6) , 1027-1039
Pyrrole–Hemoglobin Adducts, a More Feasible Potential Biomarker of Pyrrolizidine Alkaloid Exposure
Pyrrolizidine alkaloids (PAs) are naturally occurring phytotoxins widely distributed in about 3% of flowering plants. The formation of PA-derived pyrrole–protein adducts is considered as a primary trigger initiating PA-induced hepatotoxicity. The present study aims to (i) further validate our previous established derivatization method using acidified ethanolic AgNO3 for the analysis of pyrrole–protein adducts and (ii) apply this method to characterize the binding tendency, dose–response, and elimination kinetics of pyrrole–protein adducts in blood samples. Two pyrrole–amino acid conjugates, (±)-6,7-dihydro-7-hydroxy-1-hydroxymethyl-5H-pyrrolizine (DHP)–cysteine (7-cysteine-DHP) and 9-histidine-DHP, were synthesized and used to demonstrate that acidified ethanolic AgNO3 derivatization can cleave both S-linkage and N-linkage of pyrrole–protein adducts. Subsequently, using precolumn AgNO3 derivatization followed by ultra-high-pressure liquid chromatography/mass spectrometry analysis, we quantified pyrrole–protein adducts in monocrotaline-treated rat blood protein fractions, including hemoglobin (Hb), plasma, albumin, and plasma residual protein fractions, and found that the amount of pyrrole–Hb adducts was significantly higher than that in all plasma fractions. Moreover, elimination half-life of pyrrole–Hb adducts was also significantly longer than pyrrole–protein adducts in plasma fractions (12.08 vs 2.54–2.93 days). In addition, we also tested blood samples obtained from five PA-induced liver injury patients and found that the amount of pyrrole–protein adducts in blood cells was also remarkably higher than that in plasma. In conclusion, our findings for the first time confirmed that the AgNO3 derivatization method could be used to measure both S- and N-linked pyrrole–protein adducts and also suggested that pyrrole–Hb adducts with remarkably higher level and longer life span could be a better biomarker of PA exposure.
- 23 April 2019
- Published by American Chemical Society (ACS) in Chemical Research in Toxicology
- Vol. 32 (6) , 1027-1039
Pyrrole–Hemoglobin Adducts, a More Feasible Potential Biomarker of Pyrrolizidine Alkaloid Exposure
Pyrrolizidine alkaloids (PAs) are naturally occurring phytotoxins widely distributed in about 3% of flowering plants. The formation of PA-derived pyrrole–protein adducts is considered as a primary trigger initiating PA-induced hepatotoxicity. The present study aims to (i) further validate our previous established derivatization method using acidified ethanolic AgNO3 for the analysis of pyrrole–protein adducts and (ii) apply this method to characterize the binding tendency, dose–response, and elimination kinetics of pyrrole–protein adducts in blood samples. Two pyrrole–amino acid conjugates, (±)-6,7-dihydro-7-hydroxy-1-hydroxymethyl-5H-pyrrolizine (DHP)–cysteine (7-cysteine-DHP) and 9-histidine-DHP, were synthesized and used to demonstrate that acidified ethanolic AgNO3 derivatization can cleave both S-linkage and N-linkage of pyrrole–protein adducts. Subsequently, using precolumn AgNO3 derivatization followed by ultra-high-pressure liquid chromatography/mass spectrometry analysis, we quantified pyrrole–protein adducts in monocrotaline-treated rat blood protein fractions, including hemoglobin (Hb), plasma, albumin, and plasma residual protein fractions, and found that the amount of pyrrole–Hb adducts was significantly higher than that in all plasma fractions. Moreover, elimination half-life of pyrrole–Hb adducts was also significantly longer than pyrrole–protein adducts in plasma fractions (12.08 vs 2.54–2.93 days). In addition, we also tested blood samples obtained from five PA-induced liver injury patients and found that the amount of pyrrole–protein adducts in blood cells was also remarkably higher than that in plasma. In conclusion, our findings for the first time confirmed that the AgNO3 derivatization method could be used to measure both S- and N-linked pyrrole–protein adducts and also suggested that pyrrole–Hb adducts with remarkably higher level and longer life span could be a better biomarker of PA exposure.